Saturday, October 22, 2022 1:55:14 PM
I really believe that if BP is really looking at what's happening here, and at the additional trials UCLA is running with the vaccine and other therapeutics they'll start to recognize that our vaccines can enhance their therapeutics rather than threatening them.
Certainly, if you give our vaccine along with SOC treatment you get a benefit, but UCLA has shown that when you use it with other therapeutics, many of which previously failed in GBM, you get a substantially better benefit. To me, with patients living longer on the vaccine and a variety of therapeutics it's saying that BP will be selling more product when DCVax-L is approved, not less of it.
Certainly it's very possible that one or more of the BP's will want to own, or partner with NWBO. Owning the vaccine certainly may be an advantage to drug makers who have therapeutics that have synergies with the vaccine, but even if you own it, I don't believe you can prevent your competitors from using it in trials with their products. The difference is now you'd be in a position to profit from the vaccine purchased for use in your competitors trial, and success from their trial is likely to lead to even greater sales of the vaccine.
I know many believe that Merck is most likely to be the partner or buyer, certainly we'll all benefit if that is the case. In many ways I like the way Roche has dealt with companies they've partnered with, and ultimately acquired. Take Genentech, it was initially partnered, then acquired, then spun off again and finally reacquired. The point is it's been permitted to operate as a wholly owned subsidiary when it's been acquired, and Roche is free to spin it off again if it chooses to. Each time this occurred shareholders in both Roche and Genentech have done well while Roche always maintained sufficient ownership to direct what would happen next. I don't know if Roche will ever choose to have Genentech trading independently again, but the way the company is structured, it's a possibility. I suppose it would also be possible for Roche to have Genentech either partner with or acquire NWBO rather than taking it into the parent organization.
Gary
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2024 09:24:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM